Reactivation of hepatitis B: Pathogenesis and clinical implications

Current Infectious Disease Reports

Volumn 11, Issue 2, 2009, Pages 113-119

  Post, Anthony ^a   Nagendra, Shweta ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; GANCICLOVIR; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LAMIVUDINE; METHOTREXATE; NUCLEOSIDE ANALOG; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW TOXICITY; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; ENTERITIS; GRAFT REJECTION; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; NAUSEA; NONHUMAN; PANCREATITIS; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VIRUS IMMUNITY; VIRUS PATHOGENESIS; VIRUS REACTIVATION; VIRUS TRANSMISSION;

EID: 62549136124     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-009-0017-3     Document Type: Review

References (41)

1. Lalazar G, Rund D, Shouval D: Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007, 136: 699-712.
2. Yeo W, Johnson P: Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006, 43: 209-220.
3. Mindikoglu A, Regev A, Schiff E: Hepatitis B virus reactivation after cytotoxic chemotherapy: The disease and prevention. Clin Gastroenterol Hepatol 2006, 4: 1076-1081.
4. Calabrese L, Zein N, Vassilopoulos D: Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic disease: assessment and preventive strategies. Ann Rheum Dis 2006, 65: 983-989.
5. Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measure. J Viral Hepatitis 2004, 11: 97-107.
6. Perrillo R: Acute flares in chrTnic hepatitis B: the natural and unnatural history of an immunologically medicated liver disease. Gastroenterology 2001, 120: 1009-1022.
7. Kohrt H, OuyaLg D, Keeffe E: Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006, 24: 1003-1016.
8. Esteve M, Saro C, Gonzalez-Huix, et al.: Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004, 53: 1363-1365.
9. Tsai F, Hsieh S, Chen D, et al.: Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents. Dig Dis Sci 2006, 51: 1627-1632.
10. Yeo W, Chan P, Zhong S, et al.: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 2000, 62: 299-307.
11. Nakamura Y, Motokura T, Fujita A, et al.: Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies: Survey in Japan 1987-1991. Cancer 1996, 78: 2210-2215.
12. Cheng A, Hsiung C, Su I, et al.: Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBVCarriers with lymphoma. Hepatology 2003, 37: 1320-1328.
13. Lau G, Leung Y, Fong D, et al.: High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002, 99: 2324-2330.
14. Hui C, Cheung W, Au W, et al.: Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005, 54: 1597-1603.
15. Zhong S, Yeo W, Schroder C, et al.: High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 2004, 11: 55-59.
16. Chu C, Liaw Y: Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007, 133: 1458-1465.
17. Lau G, Yiu H, Fong D, et al.: Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003, 125: 1742-1749.
18. Yu A, Cheung R, Keeffe E: Hepatitis B vaccines. Infect Dis Clin North Am 2006, 20: 27-45.
19. Shouval D: Hepatitis B vaccines. J Hepatol 2003, 39: S70-S76.
20. Loomba R, RTwley A, Wesley R, et al.: Systemic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008, 148: 519-528.
21. Saab S, Dong M, Joseph T, et al.: Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: A decision analysis model. Hepatology 2007, 46: 1049-1056.
22. Martyak L, Taqavi E, Saab S: Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: A meta-analysis. Liver Int 2008, 28: 28-38.
23. Katz L, Fraser A, Gafter-Gvili A, et al.: Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: Systemic review and metaanalysis. J Viral Hepat 2008, 15: 89-102.
24. Dienstag J: Hepatitis B virus infection. N Engl J Med 2008, 359: 1486-1500.
25. Yeo W, Chan P, Ho W, et al.: Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004, 22: 927-934.
26. Yeo W, Hui E, Chan A, et al.: Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol 2005, 28: 379-384.
27. Vassiliadis T, Garipidou V, Tziomalos K, et al.: Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy: A prospective case series. Am J Hematol 2005, 80: 197-203.
28. Clark F, Drummond M, Chambers S, et al.: Successful treatment with lamivudine for fulminant reactivation hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. Ann Oncol 1998, 9: 385-387.
29. Papatheodoridis G, Dimou E, Papadimitropoulos V: Nucleoside analogues for chronic hepatitis B: Antiviral efficacy and viral resistance. Am J Gastroenterol 2002, 97: 1618-1628.
30. Persico M, Marino F, Russo G, et al.: Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002, 99: 724-725.
31. Liao C, Lee C, Wu H, et al.: Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2002, 116: 166-169.
32. Yeo W, Steinberg J, Tam J, et al.: Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 1999, 59: 263-269.
33. Cainelli F, Longhi M, Concia E, et al.: Failure of lamivudine therapy for chemotherapy-induced reactivation of hepatitis B. Am J Gastroenterol 2001, 96: 1651-1652.
34. Idilman R, Arat M, Soydan E, et al.: Lamivudine prophylaxis for prevention of chemotherapy induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 2004, 11: 141-147.
35. Idilman R: Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy. Gut 2006, 55: 1208-1209.
36. Lok A, Lai C, Leung N, et al.: Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125: 1714-1722.
37. Yen Y, Lu S, Chen C, et al.: Changes in serum hepatitis B e antigen (HbeAg) levels associated with the emergence of YMDD mutants in HbeAg non-seroconverted patients during lamivudine therapy. Liver Int 2007, 27: 1349-1355.
38. Leung N, Lai C, Chang T, et al.: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001, 33: 1527-1532.
39. Lai C, Chein R, Leung N, et al.: A one year trial of lamivudine for chronic hepatitis B. Asia hepatitis lamivudine study group. N Engl J Med 1998, 339: 61-68.
40. Liaw Y, Leung N, Chang T, et al.: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia hepatitis lamivudine study group. Gastroenterology 2000, 119: 172-80.
41. Chang T, Lai C, Chien R, et al.: Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004, 19: 1276-1282.